Volume 1, Number 3—July 1995
Streptococcal Toxic-Shock Syndrome: Spectrum of Disease, Pathogenesis, and New Concepts in Treatment
|Complication||Precentage of Patients|
|Acute respiratory distress syndrome||55|
Source: reference 1.
- Stevens DL, Tanner MH, Winship J, Swarts R, Reis KM, Schlievert PM, Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. N Engl J Med. 1989;321:1–7.
- The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA. 1993;269:390–1.
- Sennert D. De febribus libri quator. Editio novissima. Cui accessit fasciculus medicamentorum contra pestem. Libri IV. De peste, Pestilentibusque ac Malingis Febribus. Venice: Francisum Baba, 1641.
- Douglass W. The practical history of a new epidemical eruptive miliary fever, with an Angina Ulcusculosa, which prevailed in Boston, New England in the years 1735 and 1736. Boston: T. Fleet, 1736.
- Dillon HC. Impetigo contagiosa: suppurative and nonsuppurative complication. Clinical, bacteriologic and epidemiologic characteristics of impetigo. Am J Dis Child. 1968;115:530–41.
- Wannamaker LW, Rammelkamp CH Jr, Denny FW, Brink WR, Houser HB, Hahn EO, Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med. 1951;10:673–95.
- Weaver GH. Scarlet Fever. In: Abt IA, ed., Pediatrics. Philadelphia: W.B. Saunders Co., 1925:298-362.
- Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis. 1992;14:2–13.
- Kohler W, Gerlach D, Knoll H. Streptococcal outbreaks and erythrogenic toxin type A. Zbl Bakt Hyg. 1987;266:104–15.
- Martin PR, Hoiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis. 1990;22:421–9.
- Holm S. Fatal group A streptococcal infections. Presented at the 89th Conference of the American Society for Microbiology, New Orleans, LA, 1989.
- Wheeler MC, Roe MH, Kaplan EL, Schlievert PM, Todd JK. Outbreak of group A streptococcus septicemia in children: clinical, epidemiologic, and microbiological correlates. JAMA. 1991;266:533–7.
- Gaworzewska ET, Coleman G. Correspondence: group A streptococcal infections and a toxic shock-like syndrome. N Engl J Med. 1989;321:1546.
- Schwartz B, Facklam R, Breiman R. The changing epidemiology of group A streptococcal infections in the U.S.: association with changes in serotype. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990; Abstract 88.
- Bartter T, Dascal A, Carroll K, Curley FJ. "Toxic strep syndrome": manifestation of group A streptococcal infection. Arch Intern Med. 1988;148:1421–4.
- Hribalova V. Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med. 1988;108:772.
- Greenberg RN, Willoughby BG, Kennedy DJ, Otto TJ, McMillian R, Bloomster TG. Hypocalcemia and "toxic" syndrome associated with streptococcal fasciitis. South Med J. 1983;76:916–8.
- Jackson MA, Olson LC, Burry VF. Pediatric group A streptococcal (GAS) disease with multi-organ dysfunction. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990; Abstract 195.
- Thomas JC, Carr SJ, Fujioka K, Waterman SH. Community-acquired group A streptococcal deaths in Los Angeles County. J Infect Dis. 1989;160:1086–7.
- Francis J, Warren RE. Streptococcus pyogenes bacteraemia in Cambridge: a review of 67 episodes. Q J Med. 1988;256:603–13.
- Barnham M. Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteraemia in North Yorkshire. J Infect Dis. 1989;18:231–48.
- Braunstein H. Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center. Rev Infect Dis. 1991;13:8–11.
- Schwartz B, Facklam RR, Brieman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet. 1990;336:1167–71.
- Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis. 1992;166:31–7.
- Stegmayr B, Bjorck S, Holm S, Nisell J, Rydvall A, Settergren B. Septic shock induced by group A streptococcal infections: clinical and therapeutic aspects. Scand J Infect Dis. 1992;24:589–97.
- Demers B, Simor AE, Vellend H, Schlievert PM, Byrne S, Jamieson F, Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis. 1993;16:792–800.
- Auerbach SB, Schwartz B, Facklam RR, Breiman R, Jarvis WR. Outbreak of invasive group A streptococcal (GAS) disease in a nursing home. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990; Abstract 171.
- Hohenboken JJ, Anderson F, Kaplan EL. Invasive group A streptococcal (GAS) serotype M-1 outbreak in a long-term care facility (LTCF) with mortality. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994; Abstract J189.
- Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis. 1992;166:374–82.
- Belani K, Schlievert P, Kaplan E, Ferrieri P. Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr Infect Dis J. 1991;10:351–4.
- Hauser AR, Goshorn SC, Kaplan E, Stevens DL, Schlievert PM. Molecular analysis of the streptococcal pyrogenic exotoxins. Presented at the Third International American Society for Microbiology Conference on Streptococcal Genetics. Minneapolis, MN, 1990.
- Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol. 1991;29:1562–7.
- Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A. 1991;88:2668–72.
- Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest. 1993;92:710–9.
- Iwasaki M, Igarashi H, Hinuma Y, Yutsudo T. Cloning, characterization and overexpression of a Streptococcus pyogenes gene encoding a new type of mitogenic factor. FEBS Lett. 1993;331:187–92.
- Norrby-Teglund A, Newton D, Kotb M, Holm SE, Norgren M. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun. 1994;62:5227–33.
- Meleney FL. Hemolytic Streptococcus gangrene. Arch Surg. 1924;9:317–64.
- Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med. 1985;145:1020–3.
- Svane S. Peracute spontaneous streptococcal myositis: a report on 2 fatal cases with review of literature. Acta Chir Scand. 1971;137:155–63.
- Yoder EL, Mendez J, Khatib R. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. Rev Infect Dis. 1987;9:382–5.
- Nather A, Wong FY, Balasubramaniam P, Pang M. Streptococcal necrotizing myositis a rare entity: a report of two cases. Clin Orthop Relat Res. 1987;215:206–11.
- Stevens DL, Musher DM, Watson DA, Eddy H, Hamill RJ, Gyorkey F, Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis. 1990;12:286–96.
- Bullowa JGM, Wischik S. Complications of varicella. I: their occurrence among 2,534 patients. Am J Dis Child. 1935;49:923–6.
- Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun. 1989;57:291–4.
- Hackett SP, Schlievert PM, Stevens DL. Cytokine production by human mononuclear cells in response to streptococcal exotoxins. Clin Res. 1991;39:189A.
- Hallas G. The production of pyrogenic exotoxins by group A streptococci. J Hyg (Camb). 1985;95:47–7.
- Lancefield RC. Current knowledge of type specific M antigens of group A streptococci. J Immunol. 1962;89:307–13.
- Mollick JA, Rich RR. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogenes. Clin Res. 1991;39:213A.
- Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis. 1992;165:879–85.
- Kotb M, Tomai M, Majumdar G, Walker J, Beachey EH. Cellular and biochemical responses of human T lymphocytes stimulated with streptococcal M protein. Presented at the 11th Lancefield International Symposium on Streptococcal Diseases, Siena, Italy, 1990; Abstract L77.
- Watanabe-Ohnishi R, Low DE, McGeer A, Stevens DL, Schlievert PM, Newton D, Selective depletion of Vb-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J Infect Dis. 1995;171:74–84.
- Stevens DL, Bryant AE, Hackett SP. Gram-positive shock. Curr Opin Infect Dis. 1992;5:355–63.
- Hackett S, Ferretti J, Stevens D. Cytokine induction by viable group A streptococci: suppression by streptolysin O. Presented at the 93rd Conference of the American Society for Microbiology, Las Vegas, NV, 1994; Abstract B-249.
- Muller-Alouf H, Alouf JE, Gerlach D, Ozegowski JH, Fitting C, Cavaillon JM. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci and lipopolysaccharide. Infect Immun. 1994;62:4915–21.
- Hackett SP, Stevens DL. Superantigens associated with staphylococcal and streptococcal toxic shock syndromes are potent inducers of tumor necrosis factor beta synthesis. J Infect Dis. 1993;168:232–5.
- Kapur V, Majesky MW, Li LL, Black RA, Musser JM. Cleavage of Interleukin 1B (IL-1B) precursor to produce active IL-1B by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci U S A. 1993;90:7676–80.
- Cleary R, Chen C, Lapenta D, Bormann N, Heath D, Haanes E. A virulence regulon in Streptococcus pyogenes. Presented at the Third International American Society for Microbiology Conference on Streptococcal Genetics, Minneapolis, MN, 1990; Abstract 19.
- Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim MH, Hauser AR, Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet. 1992;339:518–21.
- Nida SK, Ferretti JJ. Phage influence on the synthesis of extracellular toxins in group A streptococci. Infect Immun. 1982;36:745–50.
- Johnson LP, Tomai MA, Schlievert PM. Bacteriophage involvement in group A streptococcal pyrogenic exotoxin A production. J Bacteriol. 1986;166:623–7.
- Stevens DL. Invasive group A streptococcal infections: the past, present and future. Pediatr Infect Dis J. 1994;13:561–6.
- Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr. 1985;107:681–4.
- Gatanaduy AS, Kaplan EL, Huwe BB, McKay C, Wannamaker LW. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet. 1980;2:498–502.
- Brook I. Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr Infect Dis. 1985;4:491–5.
- Kohler W. Streptococcal toxic shock syndrome. Zbl Bakt. 1990;272:257–64.
- Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med. 1952;13:389–9.
- Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23–8.
- Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents. 1994;4:297–301.
- Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis. 1993;167:1401–5.
- Yan S, Mendelman PM, Stevens DL. The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol Lett. 1993;110:313–8.
- Yan S, Bohach GA, Stevens DL. Persistent acylation of high-molecular weight penicillin-binding proteins by penicillin induces the post-antibiotic effect in Streptococcus pyogenes. J Infect Dis. 1994;170:609–14.
- Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother. 1987;31:213–8.
- Gemmell CG, Peterson PK, Schmeling D, Kim Y, Mathews J, Wannamaker L, Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest. 1981;67:1249–56.
- Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production and host response. Clin Infect Dis. 1995;20(Suppl 2):S154–7.
- Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for Toxic shock syndrome. JAMA. 1992;267:3315–6.
- Yong JM. Letter. Lancet. 1994;343:1427.
- Greenberg LJ, Gray ED, Yunis E. Association of HL-A5 and immune responsiveness in vitro to streptococcal antigens. J Exp Med. 1975;141:934–43.
- Weinstein L, Barza M. Gas gangrene. N Engl J Med. 1972;289:1129.
- Zabriskie JB, Lavenchy D, Williams RCJ, Rheumatic-fever associated B-cell alloantigens as identified by monoclonal antibodies. Arthritis Rheum. 1985;28:1047–51.
- Schwartz B, Elliot JA, Butler JC, Simon PA, Jameson BL, Welch GE, Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis. 1992;15:277–84.
Page created: December 20, 2010
Page updated: December 20, 2010
Page reviewed: December 20, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.